Frontiers and Opportunities: Highlights of the 2nd Annual Conference of the Chinese Antibody Society

Antibody Therapeutics

Volumn 1, Issue 2, 2018, Pages 65-74

  Zhang, Hongyu ^a   Deng, Mi ^b   Lin, Peng ^c   Liu, Junjian ^d   Liu, Cheng ^e   Strohl, William R ^f   Wang, Shouye ^g   Ho, Mitchell ^h  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c Fish & Richardson PC   (United States)

^d Innovent Biologics   (China)

^e EUREKA THERAPEUTICS   (United States)

^f BiStro Biotech Consulting LLC   (United States)

^g The Chinese Antibody Society   (United States)

^h NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

antibody therapeutics; biosimilars; bispecific antibodies; CAR T cells; Chinese Antibody Society

Indexed keywords

ANTIBODY; ANTIBODY DRUG CONJUGATE; BIOSIMILAR AGENT; CELL ANTIGEN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR FAMILY RECEPTOR ALPHA LIKE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR RECEPTOR; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ARTICLE; BODY WEIGHT LOSS; CANCER IMMUNOTHERAPY; CHINA; CONSENSUS DEVELOPMENT; HUMAN; IMMUNOTHERAPY; INNATE IMMUNITY; MEDICAL SOCIETY; NONHUMAN; PRIORITY JOURNAL; SCIENTIFIC LITERATURE; UNITED STATES;

EID: 85059030418     PISSN: None     EISSN: 25164236     Source Type: Journal    
DOI: 10.1093/abt/tby009     Document Type: Article

References (39)

1. Blockbuster biologics 2017: Sales of recombinant therapeutic antibodies and proteins. 2011. La Merie Publishing.
2. Moore, PA, Zhang, W, Rainey, GJ et al. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood 2011; 117: 4542-51.
3. Strohl, WR. Current progress in innovative engineered antibodies. Protein Cell 2018; 9: 86-120.
4. Park, JH, Brentjens, RJ. Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells. Discov Med 2010; 9: 277-88.
5. Themeli, M, Riviere, I, Sadelain, M. New cell sources for T cell engineering and adoptive immunotherapy. Cell Stem Cell 2015; 16: 357-66.
6. Yang, Y, Jacoby, E, Fry, TJ. Challenges and opportunities of allogeneic donor-derived CAR T cells. Curr Opin Hematol 2015; 22: 509-15.
7. Anassi, E, Ndefo, UA. Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer. P T 2011; 36: 197-202.
8. de Lima Lopes, G, Nahas, GR. Chimeric antigen receptor T cells, a savior with a high price. Chin Clin Oncol 2018; 7: 21.
9. Shi, Y, Su, H, Song, Y et al. Sintilimab (IBI308) in relapsed/refractory classical Hodgkin lymphoma: a multicenter, single-arm phase 2 trial in China (ORIENT-1 study). J Clin Oncol 2018; 36: suppl; abstr, 7536.
10. Schurch, CM, Forster, S, Bruhl, F et al. The "don't eat me" signal CD47 is a novel diagnostic biomarker and potential therapeutic target for diffuse malignant mesothelioma. Oncoimmunology 2017; 7: e1373235.
11. Hsu, JY, Crawley, S, Chen, M et al. Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15. Nature 2017; 550: 255-9.
12. Cheever, MA, Allison, JP, Ferris, AS et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15: 5323-37.
13. Dao, T, Yan, S, Veomett, N et al. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Sci Transl Med 2013; 5: 176ra133.
14. Dao, T, Pankov, D, Scott, A et al. Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. Nat Biotechnol 2015; 33: 1079-86.
15. Santich, BH, Liu, H, Liu, C et al. Generation of TCR-like antibodies using phage display. Methods Mol Biol 2015; 1348: 191-204.
16. Liu, H, Xu, Y, Xiang, J et al. Targeting alpha-fetoprotein (AFP)-MHC complex with CAR T-cell therapy for liver cancer. Clin Cancer Res 2017; 23: 478-88.
17. Li, J, Wang, S, Wang, Y et al. Disparities of trastuzumab use in resource-limited or resource-abundant regions and its survival benefit on HER2 positive breast cancer: a real-world study from China. Oncologist 2017; 22: 1333-8.
18. Allemani, C, Matsuda, T, Di Carlo, V et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018; 391: 1023-75.
19. Ferlay, J, Soerjomataram, I, Dikshit, R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-86.
20. Valabrega, G, Montemurro, F, Aglietta, M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007; 18: 977-84.
21. Park, S, Jiang, Z, Mortenson, ED et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010; 18: 160-70.
22. Ren, Z, Guo, J, Liao, J et al. CTLA-4 limits anti-CD20-mediated tumor regression. Clin Cancer Res 2017; 23: 193-203.
23. Barclay, AN, Van den Berg, TK. The interaction between signal regulatory protein alpha (SIRPalpha) and CD47: structure, function, and therapeutic target. Annu Rev Immunol 2014; 32: 25-50.
24. Liu, X, Pu, Y, Cron, K et al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med 2015; 21: 1209-15.
25. Xu, MM, Pu, Y, Han, D et al. Dendritic cells but not macrophages sense tumor mitochondrial DNA for cross-priming through signal regulatory protein alpha signaling. Immunity 2017; 47: 363-73 e365.
26. Liu, X, Kwon, H, Li, Z et al. Is CD47 an innate immune checkpoint for tumor evasion? J Hematol Oncol 2017; 10: 12.
27. Yang, X, Zhang, X, Fu, ML et al. Targeting the tumor microenvironment with interferon-beta bridges innate and adaptive immune responses. Cancer Cell 2014; 25: 37-48.
28. Ho, M. Inaugural editorial: searching for magic bullets. Antib Ther 2018; 1: 1-5.
29. Tang, Z, Qian, M, Ho, M. The role of mesothelin in tumor progression and targeted therapy. Anticancer Agents Med Chem 2013; 13: 276-80.
30. Ho, M. Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin. BioDrugs 2011; 25: 275-84.
31. Feng, M, Ho, M. Glypican-3 antibodies: a new therapeutic target for liver cancer. FEBS Lett 2014; 588: 377-82.
32. Ho, M, Kim, H. Glypican-3: a new target for cancer immunotherapy. Eur J Cancer 2011; 47: 333-8.
33. An, Z, Aksoy, O, Zheng, T et al. Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 2018; 37: 1561-75.
34. Waters, AM, Der, CJ. KRAS: the critical driver and therapeutic target for pancreatic cancer. Cold Spring Harb Perspect Med 2018; 8: a031435.
35. Shimizu, Y, Suzuki, T, Yoshikawa, T et al. Cancer immunotherapy-targeted glypican-3 or neoantigens. Cancer Sci 2018; 109: 531-41.
36. Gao, W, Tang, Z, Zhang, YF et al. Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis. Nat Commun 2015; 6: 6536.
37. Li, N, Fu, H, Hewitt, SM et al. Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma. Proc Natl Acad Sci USA 2017; 114: E6623-31.
38. Feng, M, Gao, W, Wang, R et al. Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proc Natl Acad Sci USA 2013; 110: E1083-91.
39. Sang, H, Lu, G, Liu, Y et al. Conjugation site analysis of antibody-drug-conjugates (ADCs) by signature ion fingerprinting and normalized area quantitation approach using nano-liquid chromatography coupled to high resolution mass spectrometry. Anal Chim Acta 2017; 955: 67-78.